Irma Bagdoniene: Statin Intolerance – Challenges and Solutions
Irma Bagdoniene, Cardiologist Specializing in Prevention & Lipidology, shared on LinkedIn:
“Statin intolerance: a frequent clinical challenge, but far from a dead end.
True, confirmed statin intolerance with myopathy and CK elevation occurs in about 5% of patients reporting symptoms. Many are actually experiencing the well-documented nocebo effect.
For us, this does not mean stopping therapy. It means adapting our approach.
Most patients labeled ‘intolerant’ do well after switching to another statin (for example, hydrophilic rosuvastatin) or trying low-dose, alternate-day dosing.
For those truly intolerant, therapeutic options remain robust and effective:
• Ezetimibe lowers LDL-C by 15–20%
• Bempedoic acid reduces LDL-C by 15–25% without muscle-related symptoms
• PCSK9 inhibitors provide a powerful 50–60% LDL-C reduction
• Inclisiran, with just twice-yearly dosing, delivers sustained ~60% LDL-C lowering
The CLEAR-Outcomes trial also highlighted that in statin-intolerant patients, hsCRP may predict cardiovascular risk even better than LDL-C.
The take-home message: stopping lipid-lowering therapy should be avoided wherever possible. Re-challenge, switch agents, or refer to a lipid specialist — but never leave high-risk patients unprotected. •
A highly recommended statement on this from the National Lipid Association.”
Stay with Hemostasis Today to explore more from Irma Bagdoniene.
-
May 12, 2026, 16:46Tagreed Alkaltham: Why Apheresis Matters in Modern Transfusion Medicine
-
May 12, 2026, 16:37Reinhold Kreutz: Cardiovascular Burden in Acute Intermittent Porphyria Needs Greater Awareness
-
May 12, 2026, 16:33Pablo Corral: The Truth About Very Low LDL-Cholesterol
-
May 12, 2026, 16:24Mildred Lundgren: We Must Talk About the Invisible Causes of Stroke
-
May 12, 2026, 16:17Irene Scala: The Sex Disparities In Access to Acute Stroke Treatments In Italy
-
May 12, 2026, 16:04May Nour: UCLA Health Mobile Stroke Unit Becomes The 1st In The World to Perform mCTA In the Field
-
May 12, 2026, 15:57Leonardo Roever: Prognostic Impact of Lipoprotein(a) and CAR in Elderly Acute Ischemic Stroke Patients
-
May 12, 2026, 15:54Bruno Pougault: Prioritizing Laboratory Tests in Resource-Limited Emergency Care
-
May 12, 2026, 15:37Jennifer Holter Chakrabarty: Supporting the Next Generation of Hematology Researchers